2,454.00
+4.87%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Laurus Labs
Its shares trade on NSE under the ticker LAURUSLABS.NS. It has been listed since 19 December 2016. In the fiscal year to 31 March 2026, it reported revenue of ₹68.13bn and net income of ₹8.89bn. At that date it held total assets of ₹105.11bn and shareholders' equity of ₹53.00bn.
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2016-12-19. The firm is a manufacturer of active pharmaceutical ingredients (API) for antiretroviral (ARV), oncology, cardiovascular, antidiabetics, anti-asthma and gastroenterology. The company also develops and manufactures oral solid formulations, which provide contract research and manufacturing services (CRAMS) to other global pharma companies, and produce specialty ingredients for nutraceuticals, dietary supplements and cosmeceuticals. The firm operates through four business units covering a range of therapeutic applications, including Generics API, which is engaged in the development, manufacture and sale of APIs and advanced intermediates; Generics Finished Dosage Form (FDF), which is engaged in the development and manufacture of oral solid formulations; Synthesis, which is a key starting materials, intermediates and APIs for New Chemical Entities (NCEs), and Bio, which is engaged in the recombinant products.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Dec 2016
- Employees
- 5,131
- Website
- lauruslabs.com ↗
Leadership
Pay as last reported
- Dr. Ravindranath KancherlaNon-Executive Independent Chairman of the Board₹2.6m
- Dr. Satyanarayana ChavaChief Executive Officer, Executive Director, since 2015₹131.5m
- Mr. Venkata Ravi VantaramChief Financial Officer, Executive Director, since 2015₹45.3m
- Dr. V. Uma Maheswer RaoPresident Chemical R and D, since 2023
- Mr. Srinivasa SuryadevaraPresident - Manufacturing and Operations, since 2023
- Mr. Thomas VersoskyPresident - FDF, North America
- Mr. Jyothi Basu AbbibeniExecutive Vice President - Chemical R and D
- Mr. Narasimha ChavaExecutive Vice President - Human Resources, since 2023
- Mr. Rajaram IyerExecutive Vice President Portfolio Management, since 2023
- Mr. Martyn James PeckExecutive Vice President Business Development, since 2023
- Mr. Sita RamaiahExecutive Vice President - Finance, since 2023
- Mr. Narasimha Rao DvlExecutive Vice President - Synthesis, since 2023
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 51
- Environment
- 55
- Social
- 74
- Governance
- 24
- Direct emissions (scope 1)
- 198,782 t
- Energy emissions (scope 2)
- 176,678 t
- Value chain emissions (scope 3)
- 87,212 t
- Women in the workforce
- 7%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Laurus Labs Ltd possesses several key strengths that contribute to its success and competitive advantage. These include:
Weaknesses
- Despite its strengths, Laurus Labs Ltd also faces certain weaknesses that may hinder its growth and competitiveness. These include:
Opportunities
- Laurus Labs Ltd can leverage various opportunities to enhance its market position and drive growth. These opportunities include:
Threats
- Laurus Labs Ltd faces certain threats that could impact its business performance and market position, including:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.